false
0001888886
True
0001888886
2025-08-06
2025-08-06
0001888886
gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember
2025-08-06
2025-08-06
0001888886
gpcr:OrdinarySharesParValue0.0001PerShareMember
2025-08-06
2025-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 6, 2025
Structure
Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
| Cayman
Islands |
|
001-41608 |
|
98-1480821 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File
Number) |
|
(IRS Employer
Identification
No.) |
601
Gateway Blvd., Suite 900
South
San Francisco, California |
|
94080 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
(Registrant’s telephone number, including
area code): (650) 457-1978
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| ¨ |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
| Title
of Each Class |
|
Name Of Each Exchange
Trading Symbol(s) |
|
On Which
Registered |
American
Depositary Shares (ADSs), each representing three
ordinary shares, par value $0.0001 per ordinary share |
|
GPCR |
|
Nasdaq
Global Market |
| |
|
|
|
|
| Ordinary
shares, par value $0.0001 per share* |
|
True |
|
Nasdaq
Global Market* |
* Not for trading, but only in connection with the registration of
the American Depositary Shares
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2025, Structure Therapeutics Inc. (the “Company”)
issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2025.
The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein
by reference.
The information in this Current Report on Form 8-K (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated
by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. | |
Description |
| | |
|
| 99.1 | |
Press Release dated August 6, 2025 |
| | |
|
| 104 | |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Structure Therapeutics Inc. |
| |
|
| Date: August 6, 2025 |
By: |
/s/ Raymond Stevens |
| |
|
Raymond Stevens, Ph.D. |
| |
|
Chief Executive Officer |
